SOURCE: ZELTIQ Aesthetics, Inc.

ZELTIQ Aesthetics, Inc.

February 29, 2016 16:12 ET

ZELTIQ Announces Chief Financial Officer Transition

Appoints Taylor C. Harris as Chief Financial Officer

PLEASANTON, CA--(Marketwired - February 29, 2016) -  ZELTIQ®, (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, has appointed Taylor C. Harris to the position of Senior Vice President and Chief Financial Officer, effective April 18, 2016. Mr. Harris will succeed outgoing Senior Vice President and Chief Financial Officer, Patrick F. Williams, who will be leaving to pursue other opportunities. Mr. Williams will remain with ZELTIQ in the Chief Financial Officer role until April 18th at which time he will transition into a consulting role in order to provide ongoing support and transition services.

Mr. Harris previously served as Vice President and Chief Financial Officer at Thoratec Corporation from October 2012 until October 2015 when Thoratec was acquired by St. Jude Medical, Inc. Mr. Harris joined Thoratec as its Senior Director of Investor Relations and Business Development in February 2010. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a B.A. in Physics and Economics from the University of North Carolina at Chapel Hill.

"With his deep experience in the medical device industry, Taylor comes to ZELTIQ well equipped to provide strong financial, operational, and strategic leadership during this period of robust global growth we are experiencing," commented Mark Foley, ZELTIQ's President and Chief Executive Officer. "We are very excited to have Taylor join our senior executive team, and we look forward to benefitting from his insights and contributions as we continue to scale our business."

"I am thrilled to join ZELTIQ," said Mr. Harris. "ZELTIQ has revolutionized noninvasive fat reduction and has developed a clear market leadership position. I look forward to working with the talented team at ZELTIQ to drive further success for the company and to capitalize on the exciting range of growth opportunities ahead."

"My three-plus years at ZELTIQ have been incredibly rewarding as part of a management team that has helped build and maintain a global leadership position in non-invasive fat reduction," said Mr. Williams, Senior Vice President and Chief Financial Officer. "While my experience at ZELTIQ has been incredibly fulfilling, I am eager to take on my next challenge. I would like to thank everyone at ZELTIQ that made my time here an exceptional one."

"I would like to thank Patrick for his years of dedicated service to ZELTIQ and for the many contributions he has made to our growth and success," said Mr. Foley. "Patrick has been an integral part of the management team and has led the finance and information technology organizations through a period of tremendous growth. We wish him well in his future endeavors."

About ZELTIQ ®

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.